Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
We previously published in the Journal of Thoracic Oncology the case of a patient with EGFR and MET-driven lung cancer and extracranial response to capmatinib and osimertinib. Here, we report on a second patient treated with the same combination, revealing complete and durable intracranial response....
Main Authors: | Oliver Gautschi, MD, Joachim Diebold, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-04-01
|
Series: | JTO Clinical and Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364321000217 |
Similar Items
-
Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
by: Molly Wilgucki, DO, et al.
Published: (2022-10-01) -
Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report
by: Siqi Xiang, et al.
Published: (2023-11-01) -
Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature
by: Daniel S Lefler, et al.
Published: (2022-12-01) -
Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
by: Chien-Yu Lin, et al.
Published: (2022-08-01) -
Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
by: Fionnuala Crowley, MB BCh BAO, et al.
Published: (2022-01-01)